Search

Your search keyword '"Plazier, Mark"' showing total 209 results
Start Over Author "Plazier, Mark"
209 results on '"Plazier, Mark"'

7. Transforaminal epidural steroid injection for radiculopathy and the evolution to surgical treatment: a pragmatic prospective observational multicenter study

Author

Raymaekers, Vincent, primary, Roosen, Gert, additional, Put, Eric, additional, Vanvolsem, Steven, additional, Achahbar, Salah-Eddine, additional, Meeuws, Sacha, additional, Wissels, Maarten, additional, Bamps, Sven, additional, Ridder, Dirk De, additional, Menovsky, Tomas, additional, and Plazier, Mark, additional

Published
2024
Full Text
View/download PDF

9. RF008 / #350 COMBINED SUPRA-ORBITAL AND OCCIPITAL NERVE STIMULATION FOR REFRACTORY CHRONIC MIGRAINE – IMPLANTATION TECHNIQUE AND EARLY FEASIBILITY WITH A NOVEL NEUROSTIMULATION SYSTEM

Author

Plazier, Mark, primary, Billet, Bart, additional, Hanssens, Karel, additional, De Vos, Ruben, additional, Goethals, Maarten, additional, Akram, Harith, additional, Frank, Paul, additional, Green, Alexander, additional, Meier, Kaare, additional, Nijhuis, Harold, additional, Palmisani, Stefano, additional, Raymaekers, Vincent, additional, Spincemaille, Geert, additional, Toma, Ahmed, additional, Watkins, Laurence, additional, and Huygen, Frank, additional

Published
2023
Full Text
View/download PDF

10. EP054 / #250 SPINAL CORD STIMULATOR TIP LOCATION DOES NOT CORRELATE WITH ABDOMINAL WALL STIMULATION: FIRST RESULTS FROM THE CAWSAN STUDY: A NON-RANDOMIZED CLINICAL TRIAL

Author

Raymaekers, Vincent, primary, Vanloon, Maarten, additional, Roosen, Gert, additional, Put, Eric, additional, Wissels, Maarten, additional, Vanvolsem, Steven, additional, Klein, Samuel, additional, Achahbar, Salah-Eddine, additional, Bamps, Sven, additional, Meeuws, Sacha, additional, and Plazier, Mark, additional

Published
2023
Full Text
View/download PDF

14. Peripheral Nerve Stimulation

Author

Slavin, Konstantin V., Carayannopoulos, Alexios G., Plazier, Mark, Vanneste, Sven, De Ridder, Dirk, Knotkova, Helena, editor, and Rasche, Dirk, editor

Published
2015
Full Text
View/download PDF

23. Lateral lumbar interbody fusion (LLIF/DLIF/XLIF) versus posterior lumbar interbody fusion (PLIF) surgery in spinal degenerative disease: a systematic review

Author

Sven, Bamps, Raymaekers, Vincent, Roosen, Gert, Put, Eric, Vanvolsem, Steven, Achahbar, Salah-Eddine, Meeuws, Sacha, Wissels, Maarten, and Plazier, Mark

Abstract

Degenerative diseases of the lumbar spine are often treated with posterior interbody fusion surgery (PLIF) for spinal instability or intractable back pain with neurological impairment. Several lateral, less invasive procedures have been recently described (LLIF/DLIF/XLIF). The aim of this systematic review is to compare structural and functional outcomes of lateral surgical approaches to PLIF.We conducted a Medline (Pubmed), Web of Science, Science direct and Cochrane Library search for studies focusing on outcomes and complications comparing lateral lumbar interbody fusion (LLIF/DLIF/XLIF) and posterior lumbar interbody fusion (PLIF). The systematic review was reported using the PRISMA criteria.In total 1000 research articles were identified of which five studies were included comparing the outcomes and complications between the lateral and posterior approach. Three studies found significant less perioperative blood loss with a lateral approach. Average hospital stay was shorter in populations which underwent the lateral approach compared to PLIF. Functional outcomes (VAS/ODI) were similar or better with lateral lumbar interbody fusion. In the majority of the included studies, complication rates did not differ between the posterior and lateral approach. Most of the neurological deficits with XLIF/LLIF were temporary and healed completely within one-year follow up.A lateral approach (XLIF/LLIF) is a good and safe alternative for posterior lumbar interbody fusion in single level degenerative lumbar diseases with comparable functional outcomes, shorter hospital stays and less blood loss. Future prospective studies are needed to establish the role of lateral, minimally invasive approaches in spinal degenerative surgery.

Published
2022

24. PO048 / #665 THE BIG CHANGE IS COMMING: BIG DATA

Author

Plazier, Mark, primary, Raymaekers, Vincent, additional, Duyvendak, Wim, additional, Meeuws, Sacha, additional, Wissels, Maarten, additional, Vanvolsem, Steven, additional, Roosen, Gert, additional, Bamps, Sven, additional, Achabar, Salah-Edine, additional, Schu, Stefan, additional, Keil, Anna, additional, Schultheis, Björn Carsten, additional, Slotty, Philipp, additional, De Ridder, Dirk, additional, and Vesper, Jan, additional

Published
2022
Full Text
View/download PDF

34. Personalised rehabilitation to improve return to work in patients with persistent spinal pain syndrome type II after spinal cord stimulation implantation: a study protocol for a 12-month randomised controlled trial-the OPERA study.

Author

Moens, Maarten, Goudman, Lisa, Van de Velde, Dominique, Godderis, Lode, Putman, Koen, Callens, Jonas, Lavreysen, Olivia, Ceulemans, Dries, Leysen, Laurence, OPERA consortium, Van Buyten, Jean-Pierre, Smet, Iris, Jerjir, Ali, Bryon, Bart, Plazier, Mark, Raymaekers, Vincent, Schelfout, Sam, Crombez, Erwin, Theys, Tom, and Van Hoylandt, Anaïs

Subjects
SPINAL cord, RANDOMIZED controlled trials, CHRONIC pain, SLEEP quality, DEEP brain stimulation, RESEARCH protocols
Abstract

Background: For patients with therapy-refractory persistent spinal pain syndrome type II (PSPS-T2), spinal cord stimulation (SCS) may serve as an effective minimally invasive treatment. Despite the evidence that SCS can improve return to work (RTW), only 9.5 to 14% of patients implanted with SCS are effectively capable of returning to work. Thus, it seems that current post-operative interventions are not effective for achieving RTW after SCS implantation in clinical practice. The current objective is to examine whether a personalised biopsychosocial rehabilitation programme specifically targeting RTW alters the work ability in PSPS-T2 patients after SCS implantation compared to usual care.Methods: A two-arm, parallel-group multicentre randomised controlled trial will be conducted including 112 patients who will be randomised (1:1) to either (a) a personalised biopsychosocial RTW rehabilitation programme of 14 weeks or (b) a usual care arm, both with a follow-up period until 12 months after the intervention. The primary outcome is work ability. The secondary outcomes are work status and participation, pain intensity, health-related quality of life, physical activity and functional disability, functional capacities, sleep quality, kinesiophobia, self-management, anxiety, depression and healthcare expenditure.Discussion: Within the OPERA project, we propose a multidisciplinary personalised biopsychosocial rehabilitation programme specifically targeting RTW for patients implanted with SCS, to tackle the high socio-economic burden of patients that are not re-entering the labour market. The awareness is growing that the burden of PSPS-T2 on our society is expected to increase over time due to the annual increase of spinal surgeries. However, innovative and methodologically rigorous trials exploring the potential to decrease the socio-economic burden when patients initiate a trajectory with SCS are essentially lacking.Trial Registration: ClinicalTrials.gov NCT05269212. Registered on 7 March 2022. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Peripheral Nerve Stimulation

Author

Slavin, Konstantin V., primary, Carayannopoulos, Alexios G., additional, Plazier, Mark, additional, Vanneste, Sven, additional, and De Ridder, Dirk, additional

Published
2014
Full Text
View/download PDF

44. What to know about schwannomatosis: a literature review

Author

Schraepen, Cedric, DONKERSLOOT, Peter, DUYVENDAK, Wim, PLAZIER, Mark, PUT, Eric, Roosen, Gert, Vanvolsem, Steven, Wissels, Maarten, and BAMPS, Sven

Subjects
NF2 gene, Schwannomatosis, Schwannoma, Neurofibromatosis
Abstract

Background Schwannomatosis is a relatively rare disorder and is related to neurofibromatosis type 2. Although there is clinical overlap between schwannomatosis and neurofibromatosis type 2, these diseases have to be regarded as separate entities due to the genetic origin and course of the disease. Methods A comprehensive review of the literature was conducted for relevant studies using Pubmed and Cochrane databases to discuss the epidemiology, clinical presentation, diagnostic criteria, pathological and imaging features, treatment and genetics of schwannomatosis. Results Germline mutations SMARCB1 and LZTRI together with the NF2 gene play a role in the pathophysiology of schwannomatosis. The most common symptom is pain with affection of the spine and peripheral nerves in the majority of patients. High quality contrast enhanced MRI scan is the imaging modality of choice. Treatment is conservative if asymptomatic and surgical if symptomatic. The goal is symptom control with preservation of neurological function. Conclusion Schwannomatosis is a relatively rare disorder in which the main goal is to preserve neurological function. Schraepen, C (corresponding author), Katholieke Univ Leuven, Fac Med & Life Sci, Leuven, Belgium. cedric.schraepen@student.kuleuven.be

Published
2020

45. What to know about schwannomatosis: a literature review

Author

Schraepen, Cédric, primary, Donkersloot, Peter, additional, Duyvendak, Wim, additional, Plazier, Mark, additional, Put, Eric, additional, Roosen, Gert, additional, Vanvolsem, Steven, additional, Wissels, Maarten, additional, and Bamps, Sven, additional

Published
2020
Full Text
View/download PDF

47. What to know about schwannomatosis: a literature review.

Author

Schraepen, Cédric, Donkersloot, Peter, Duyvendak, Wim, Plazier, Mark, Put, Eric, Roosen, Gert, Vanvolsem, Steven, Wissels, Maarten, and Bamps, Sven

Subjects
NEUROFIBROMATOSIS 2, LITERATURE reviews, GENETICS, NEUROFIBROMATOSIS 1, SYMPTOMS, PERIPHERAL nervous system
Abstract

Schwannomatosis is a relatively rare disorder and is related to neurofibromatosis type 2. Although there is clinical overlap between schwannomatosis and neurofibromatosis type 2, these diseases have to be regarded as separate entities due to the genetic origin and course of the disease. A comprehensive review of the literature was conducted for relevant studies using Pubmed and Cochrane databases to discuss the epidemiology, clinical presentation, diagnostic criteria, pathological and imaging features, treatment and genetics of schwannomatosis. Germline mutations SMARCB1 and LZTRI together with the NF2 gene play a role in the pathophysiology of schwannomatosis. The most common symptom is pain with affection of the spine and peripheral nerves in the majority of patients. High quality contrast enhanced MRI scan is the imaging modality of choice. Treatment is conservative if asymptomatic and surgical if symptomatic. The goal is symptom control with preservation of neurological function. Schwannomatosis is a relatively rare disorder in which the main goal is to preserve neurological function. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results